Q. What is Neurofibromatosis?
 

Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum.

Neurofibromatosis Type 1 (NF1)

Q. What is the genetic basis of NF1?
 

NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation.

Q. What is the inheritance pattern?
 

NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations.

Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)?
 

Diagnosis requires two or more of the following:
 

1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal).
 

2. Two or more neurofibromas of any type, or one plexiform neurofibroma.
 

3. Axillary or inguinal freckling (Crowe sign).
 

4. Optic pathway glioma.
 

5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography).
 

6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone.

 

7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 
 

8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.)

Q. What are the additional supportive (nonessential) features of NF1?
 

Macrocephaly, short stature, and learning disabilities or ADHD.
Seizures, developmental delay, or autism spectrum traits.
Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia.
Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease).
Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma).
Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas.
Choroidal hamartomas visible on near-infrared OCT.
Elephantiasis neuromatosa from plexiform neurofibroma overgrowth.

Q. What are the clinical features of NF1?
 

Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas.
Ophthalmic: Lisch nodules, optic pathway glioma.
Neurologic: learning disability, ADHD, seizures, headaches.
Skeletal: scoliosis, bone dysplasia.
Tumors: MPNST, astrocytoma, pheochromocytoma.

Q. What are the radiologic findings?
 

MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions.

Q. How is NF1 managed?
 

Observation for asymptomatic lesions.
Surgical excision for symptomatic or disfiguring neurofibromas.
Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome.

Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic.
MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy.

Q. What is the prognosis?
 

Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis.

Neurofibromatosis Type 2 (NF2)

Q. What is the genetic basis of NF2?
 

NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation.

Q. What is the inheritance pattern?
 

NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic.

Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)?
 

Diagnosis can be made by:
1. Bilateral vestibular schwannomas, or
2. A first-degree relative with NF2-related schwannomatosis plus either
- unilateral vestibular schwannoma, or
- any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract.
3. NF2 pathogenic variant in blood or tumor, with compatible clinical features.

Q. What are supportive clinical features of NF2?
 

Bilateral vestibular schwannomas (pathognomonic).
Multiple meningiomas (intracranial and spinal).
Spinal ependymomas and schwannomas.
Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas.
Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots).
Cranial neuropathies and hearing loss as early symptoms.
Family history of early-onset hearing loss or CNS tumors.

Q. What is the typical age of presentation?
 

Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2.

Q. What are the imaging findings?
 

MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas.
MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas.

Q. How is NF2 managed?
 

MRI surveillance (brain and spine every 12–24 months).
Microsurgery or radiosurgery for symptomatic tumors.
Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing.
Rehabilitation with cochlear or brainstem implants for hearing loss.
Genetic counseling for family.

Q. What is the prognosis?
 

Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression.

Schwannomatosis

Q. What is schwannomatosis?
 

Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum.

Q. What is the genetic basis?
 

Three defined molecular subtypes:
1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12).
2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23).
3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23).

Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell.

Q. What is the inheritance pattern?
 

Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic.

Q. What are the diagnostic criteria (2022 update)?
 

Clinical diagnosis:
- Two or more non-intradermal schwannomas confirmed histologically.
- No bilateral vestibular schwannomas on MRI.
- No constitutional NF2 mutation or first-degree relative with NF2.

Molecular diagnosis:
- Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement.

Q. What are the clinical features?
 

Chronic or paroxysmal pain (hallmark symptom).
Palpable nerve masses along peripheral or spinal nerves.
No vestibular or hearing symptoms.
Minimal skin lesions, no café-au-lait spots or Lisch nodules.
May have mononeuropathies or focal weakness due to nerve compression.

Q. What are the radiological features?
 

MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas.
Diffusion and contrast help differentiate from meningiomas or neurofibromas.

Q. What are the histopathological findings?
 

Typical schwannoma pattern:
- Antoni A and Antoni B areas.
- Verocay bodies in Antoni A.
- Strong S-100 positivity.
- No entrapped axons (unlike neurofibroma).

Q. What are the differences among genetic subtypes?
 

SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas.
LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma.
NF2-related: mosaic or milder NF2 phenotype.

Q. How is schwannomatosis managed?
 

Surgical resection of symptomatic schwannomas.
Pain control with neuropathic agents and nerve blocks.
MRI surveillance every 2–3 years.
Genetic counseling for family.
No established drug therapy; bevacizumab is ineffective except in NF2-related cases.

Q. What is the prognosis?
 

Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries.

Histologic Discussion: Schwannoma vs Neurofibroma

Q. How do schwannoma and neurofibroma differ?
 

Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy.
 

Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk.
 

Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma.

Q. What are Antoni A and Antoni B areas, and Verocay bodies?
 

Antoni A areas are hypercellular and organized with nuclear palisading.
Antoni B areas are hypocellular, myxoid, and loosely arranged.
Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma.

Q. What is segmental or mosaic NF?
 

A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring.

Q. What is plexiform neurofibroma and why is it significant?
 

Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST.

Q. What is MPNST?
 

A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance.

Genetic mechanisms of tumorigenesis:
Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation.
NF1: RAS pathway dysregulation.
NF2: loss of contact inhibition via merlin deficiency.

Follow-up protocols:
NF1 – annual BP, neuro and eye exams, MRI if symptomatic.
NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly.
Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring.

Final recall summary:
NF1 = Peripheral + Pigmentary.
NF2 = Central + Vestibular.
Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.